Start up. Grow up. Succeed.

News 2015

Sanofi and MAB Discovery sign collaboration agreement for the

Sanofi and MAB Discovery GmbH entered into a research and license agreement in the field of monoclonal antibodies.

SimScale secures Series A financing round led by Union Square Ventures for its web-based simulation technology

SimScale, the web-based simulation company, today announced it has closed its Series A funding round, led by Union Square Ventures with support from Earlybird Venture Capital and angel investor Axel Bichara. The funding will be used to accelerate its vision of bringing high-performance 3D simulation technology to designers and engineers everywhere.

Sanofi and BioNTech Announce Cancer Immunotherapy Collaboration and License Agreement

Paris, France and Mainz, Germany - November 3, 2015 - Sanofi and BioNTech A.G. today announced that they have entered into a multiyear exclusive collaboration and license agreement. This research collaboration between Sanofi and BioNTech will leverage the scientific expertise of the two organizations to discover and develop up tofive cancer immunotherapies, each consisting of a mixture of synthetic messenger RNAs (mRNAs).

Filgen and PEPperPRINT sign distribution agreement for Japan

PEPperPRINT has signed a distribution agreement with Filgen for Japan.

13th CIMT Annual Meeting & CIMT Endeavour

The right patient for the right therapy The 13th Annual Meeting of the Association for Cancer Immunotherapy connects the global cancer immunotherapy community in the heart of Europe.

Pieris Pharmaceuticals and The University of Melbourne Receive Research Grant to Advance Immunological Diseases Program

FREISING, GERMANY and MELBOURNE, AUSTRALIA -- (Marketwired) -- 03/30/15 Pieris Pharmaceuticals, Inc. (OTCQB: PIRS) and The University of Melbourne today announced the receipt by the University of a research grant to further develop Pieris' novel protein Anticalin®-brand therapeutic, PRS-060, in immunological diseases.

Nexigen GmbH receives BMBF grant

Nexigen GmbH has been awarded a grant of approximately 1.0 million Euro by the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung – BMBF) under the KMU-Innovation Programme.

Nexigen GmbH closes 5.6 Million Euro financing

Nexigen GmbH closed a further financing round totaling 5.6 million Euro with the participation of existing investors AT Newtec GmbH, FCPB Nex GmbH and MIG Fonds.